AU2016222804C1 - 5HT agonists for treating disorders - Google Patents

5HT agonists for treating disorders Download PDF

Info

Publication number
AU2016222804C1
AU2016222804C1 AU2016222804A AU2016222804A AU2016222804C1 AU 2016222804 C1 AU2016222804 C1 AU 2016222804C1 AU 2016222804 A AU2016222804 A AU 2016222804A AU 2016222804 A AU2016222804 A AU 2016222804A AU 2016222804 C1 AU2016222804 C1 AU 2016222804C1
Authority
AU
Australia
Prior art keywords
receptor agonist
receptor
pharmaceutically acceptable
clemizole
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016222804A
Other languages
English (en)
Other versions
AU2016222804A1 (en
AU2016222804B2 (en
Inventor
Scott C. Baraban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2016222804A1 publication Critical patent/AU2016222804A1/en
Priority to AU2021204261A priority Critical patent/AU2021204261B2/en
Publication of AU2016222804B2 publication Critical patent/AU2016222804B2/en
Application granted granted Critical
Publication of AU2016222804C1 publication Critical patent/AU2016222804C1/en
Priority to AU2022203274A priority patent/AU2022203274B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016222804A 2015-02-25 2016-02-24 5HT agonists for treating disorders Active AU2016222804C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021204261A AU2021204261B2 (en) 2015-02-25 2021-06-23 5ht agonists for treating disorders
AU2022203274A AU2022203274B2 (en) 2015-02-25 2022-05-16 5HT agonists for treating disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25
US62/120,726 2015-02-25
PCT/US2016/019368 WO2016138138A1 (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021204261A Division AU2021204261B2 (en) 2015-02-25 2021-06-23 5ht agonists for treating disorders

Publications (3)

Publication Number Publication Date
AU2016222804A1 AU2016222804A1 (en) 2017-08-31
AU2016222804B2 AU2016222804B2 (en) 2021-07-15
AU2016222804C1 true AU2016222804C1 (en) 2021-10-14

Family

ID=56789223

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016222804A Active AU2016222804C1 (en) 2015-02-25 2016-02-24 5HT agonists for treating disorders
AU2021204261A Active AU2021204261B2 (en) 2015-02-25 2021-06-23 5ht agonists for treating disorders
AU2022203274A Active AU2022203274B2 (en) 2015-02-25 2022-05-16 5HT agonists for treating disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021204261A Active AU2021204261B2 (en) 2015-02-25 2021-06-23 5ht agonists for treating disorders
AU2022203274A Active AU2022203274B2 (en) 2015-02-25 2022-05-16 5HT agonists for treating disorders

Country Status (21)

Country Link
US (4) US10874643B2 (enExample)
EP (3) EP3632434A1 (enExample)
JP (5) JP6884703B2 (enExample)
KR (3) KR102385665B1 (enExample)
CN (2) CN107530326B (enExample)
AU (3) AU2016222804C1 (enExample)
BR (1) BR112017018297B1 (enExample)
CA (2) CA3204599A1 (enExample)
CY (1) CY1125360T1 (enExample)
DK (1) DK3261640T3 (enExample)
EA (2) EA201992474A3 (enExample)
ES (1) ES2920886T3 (enExample)
HR (1) HRP20220822T1 (enExample)
HU (1) HUE059559T2 (enExample)
LT (1) LT3261640T (enExample)
PL (1) PL3261640T3 (enExample)
PT (1) PT3261640T (enExample)
RS (1) RS63426B1 (enExample)
SI (1) SI3261640T1 (enExample)
SM (1) SMT202200276T1 (enExample)
WO (1) WO2016138138A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
AU2016222804C1 (en) 2015-02-25 2021-10-14 The Regents Of The University Of California 5HT agonists for treating disorders
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CA3007286A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020018839A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Compounds and methods for synergistic activation of m channels
BR112021001135A2 (pt) * 2018-07-27 2021-04-20 Xenon Pharmaceuticals Inc. compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
JP2022535744A (ja) * 2019-05-29 2022-08-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア てんかんを治療するための方法および組成物
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
CN114901270A (zh) * 2019-10-23 2022-08-12 地图之光治疗股份有限公司 治疗自闭症谱系障碍的症状的方法
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
AU2020395254A1 (en) * 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
EP4313037A4 (en) * 2021-03-25 2025-02-26 MapLight Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN
WO2022256267A1 (en) * 2021-06-01 2022-12-08 Arena Pharmaceuticals, Inc. Methods of treatment
EP4351586A4 (en) * 2021-06-10 2025-04-02 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
JP2024529509A (ja) * 2021-07-30 2024-08-06 エピジェニクス セラピューティクス インコーポレーテッド クレミゾール製剤
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions
US20240174594A1 (en) * 2022-11-30 2024-05-30 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2015026849A1 (en) * 2013-08-19 2015-02-26 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036586A2 (en) 2006-09-20 2008-03-27 Waters Investments Limited Apparatus and methods of fluid chromatography
EP2134556B1 (en) 2007-04-06 2012-07-18 Koninklijke Philips Electronics N.V. Air pollution sensor system
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008138123A1 (en) 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
WO2010107742A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
KR20100137473A (ko) 2008-02-19 2010-12-30 아돌로 코포레이션 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체
US20110040105A1 (en) 2008-04-16 2011-02-17 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1--2-methyl-pyrrolidine
EP2307035B1 (en) 2008-05-16 2013-12-04 NoNO Inc. Use of an inhibitor of psd-95treatment for epilepsy
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US8772479B2 (en) 2009-05-13 2014-07-08 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
US20150313913A1 (en) * 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
AU2016222804C1 (en) 2015-02-25 2021-10-14 The Regents Of The University Of California 5HT agonists for treating disorders
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2015026849A1 (en) * 2013-08-19 2015-02-26 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Baraban, SC et al (2013) Nature Communications 4: 1-10 *
Griffin, AL et al (2019) 'Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome' Brain Communications 1(1):fcz008 *
Richter, JM et al (2014) Molecular Pharmacology 86: 514-521 *

Also Published As

Publication number Publication date
JP2020143087A (ja) 2020-09-10
DK3261640T3 (da) 2022-07-11
CA3204599A1 (en) 2016-09-01
CA2977135A1 (en) 2016-09-01
EP3261640A1 (en) 2018-01-03
EP4043016A1 (en) 2022-08-17
CY1125360T1 (el) 2025-05-09
JP6884703B2 (ja) 2021-06-09
JP2022116307A (ja) 2022-08-09
AU2016222804A1 (en) 2017-08-31
HRP20220822T1 (hr) 2022-10-28
WO2016138138A1 (en) 2016-09-01
RS63426B1 (sr) 2022-08-31
LT3261640T (lt) 2022-07-11
AU2022203274A1 (en) 2022-06-16
EP3261640A4 (en) 2018-12-19
JP2021185148A (ja) 2021-12-09
EA201791882A1 (ru) 2018-02-28
AU2021204261A1 (en) 2021-07-29
EA201992474A3 (ru) 2020-05-31
EP4043016B1 (en) 2025-10-29
AU2016222804B2 (en) 2021-07-15
CN107530326B (zh) 2021-09-21
EP3261640B1 (en) 2022-04-06
BR112017018297A2 (pt) 2018-04-17
CN107530326A (zh) 2018-01-02
KR20220048045A (ko) 2022-04-19
US20180028499A1 (en) 2018-02-01
PL3261640T3 (pl) 2022-10-31
KR102385665B1 (ko) 2022-04-14
US11648237B2 (en) 2023-05-16
KR20170118870A (ko) 2017-10-25
US10874643B2 (en) 2020-12-29
EA201992474A2 (ru) 2020-02-28
AU2022203274B2 (en) 2024-08-15
SI3261640T1 (sl) 2022-10-28
BR112017018297B1 (pt) 2023-12-05
CA2977135C (en) 2023-08-22
US20200147048A1 (en) 2020-05-14
AU2021204261B2 (en) 2023-08-10
US20210154171A1 (en) 2021-05-27
SMT202200276T1 (it) 2022-09-14
US20230346750A1 (en) 2023-11-02
ES2920886T3 (es) 2022-08-11
JP2024009839A (ja) 2024-01-23
CN113546174A (zh) 2021-10-26
US12447144B2 (en) 2025-10-21
JP2018506555A (ja) 2018-03-08
KR20230152844A (ko) 2023-11-03
HUE059559T2 (hu) 2022-12-28
PT3261640T (pt) 2022-07-06
EP3632434A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
AU2022203274B2 (en) 5HT agonists for treating disorders
US12419866B2 (en) Compounds and methods for treating an epileptic disorder
HK40079848A (en) The 5ht agonist clemizole for use in treating epilepsy disorders
HK40062533A (zh) 用於治疗病症的5ht激动剂
HK40016257A (en) Compounds and methods for treating an epileptic disorder
EA040818B1 (ru) Способ лечения эпилептического расстройства с помощью агониста рецептора 5ht
EA046651B1 (ru) Агонисты 5ht для лечения нарушений
HK1225984B (en) Compounds and methods for treating an epileptic disorder

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUN 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 29 JUN 2021

FGA Letters patent sealed or granted (standard patent)